|Bid||37.91 x 1000|
|Ask||38.15 x 1000|
|Day's Range||34.69 - 39.73|
|52 Week Range||19.38 - 71.50|
|Beta (5Y Monthly)||2.41|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Cowen analyst Joseph Thome said the disclosure is "an encouraging sign and hopefully an important step toward a potential near-term FDA approval" of Axsome's drug for major depressive disorder.
The stock market was in rally mode last week, and the good vibes looked like they were continuing after the weekend. As of 8:30 a.m., futures on the Nasdaq Composite (NASDAQINDEX: ^IXIC) led the market higher, rising about half a percent to climb above the 12,200 mark. Investors have been more interested in stock splits than ever, and some big-name companies have joined in the trend.
Axsome Therapeutics (NASDAQ: AXSM), a newly minted commercial-stage biopharma, is set for a strong session today. Ahead of the opening bell this morning, Axsome released an 8-K filing with the Securities and Exchange Commission revealing that it has received the proposed labeling from the Food and Drug Administration (FDA) for the experimental major depressive disorder drug known as AXS-05. The FDA reportedly sent Axsome this long-awaited regulatory update last Friday.